Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102998 | 0.91 | EPHX2 (0.59) | EPHX2EPHX1CACNA1HKMT2AMEN1 | |
| SCHEMBL17586281 | 0.77 | EPHX2 (0.46) | EPHX2EPHX1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11959258 | 0.75 | EPHX2 (0.55) | EPHX2EPHX1CACNA1HKMT2AMEN1 | |
| SCHEMBL16037882 | 0.73 | — | — | |
| SCHEMBL11941695 | 0.72 | KMT2A (0.53) | EPHX2EPHX1CACNA1HKMT2AMEN1 | |
| SCHEMBL17586286 | 0.72 | MEN1 (0.63) | EPHX2EPHX1CACNA1HKMT2AMEN1 | |
| SCHEMBL17586263 | 0.71 | DPP8 (0.32) | DPP8DPP9 | |
| SCHEMBL25347526 | 0.70 | — | — | |
| SCHEMBL21427871 | 0.70 | EPHX2 (0.48) | EPHX2EPHX1KMT2ASMN1; SMN2GAA | |
| SCHEMBL21428090 | 0.70 | EPHX2 (0.48) | EPHX2EPHX1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20210179617-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3193855-B1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | EPHX2 295/4885EPHX1 164/4885CACNA1H 3828/4885 |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | EPHX2 420/4885EPHX1 1140/4885CACNA1H 1135/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | EPHX2 295/4885EPHX1 164/4885CACNA1H 3828/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | EPHX2 420/4885EPHX1 1140/4885CACNA1H 1135/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | EPHX2 420/4885EPHX1 1140/4885CACNA1H 1135/4885 |
| US-20210179617-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | EPHX2 1901/4885EPHX1 1717/4885CACNA1H 3211/4885 |
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | EPHX2 420/4885EPHX1 1140/4885CACNA1H 1135/4885 |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | EPHX2 1901/4885EPHX1 1717/4885CACNA1H 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.